BrainStorm Cell Therapeutics Inc. Responds To The Veto Of The Stem Cell Research Enhancement Act (HR-810)

NEW YORK--(BUSINESS WIRE)--July 20, 2006--BrainStorm Cell Therapeutics (OTCBB:BCLI - News), a leading company in adult stem cell research, comments on the Stem Cell Research Enhancement Act (HR-810), which was vetoed yesterday by President Bush, and the lesser-known Alternative Pluripotent Stem Cell Therapies Enhancement Act ("S-2754 ES"), which was just passed by the Senate and is expected to be signed by President Bush today.